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PURPOSE: The incidence of sensorineural hearing loss (SNHL) after treatment with combination of intensity-
modulated radiation therapy (IMRT) and cisplatin-based chemotherapy in nasopharyngeal carcinoma (NPC)
patients was evaluated, and relationships of SNHL with host factors, treatment-related factors, and radiation
dosimetric parameters were investigated.METHODS: Fifty-one NPC patients treated with IMRT from 2004 to 2009
were analyzed. All patients received neoadjuvant, concurrent, or adjuvant use of cisplatin. Pure tone audiometry
was performed during the follow-up period with a median time of 60 months, ranging from 28 to 84 months.
Correlation of SNHL at low frequencies (pure tone average, 0.5-2 kHz) with a series of factors was analyzed.
RESULTS: Among 102 ears, 12.7% had low-frequency SNHL and 42.2% had high-frequency (4 kHz) SNHL. The
incidence of low-frequency SNHL was greater in patients with age N 40, with T-stage 4, or who received
cumulative cisplatin dose (CCD) N 200 mg/m2 (P = .034, .011, and .003, respectively) and in ears with secretory
otitis media (SOM) (P = .002). Several dosimetric parameters were found to be correlated with SNHL. Univariate
analysis showed that the minimum radiation dose to 0.1 ml highest dose volume (D0.1 ml) of the cochlea was the
best radiation-related predictive parameter. Multivariate analysis indicated that CCD, SOM, and D0.1 ml of cochlea
(P = .035, .012, and .022, respectively) were the factors associated with SNHL. CONCLUSION: For NPC patients
treated with IMRT and chemotherapy, the incidence of treatment-related SNHL was associated with CCD, D0.1 ml
of cochlea, and SOM.
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Nasopharyngeal carcinoma (NPC) has been considered as one of the
rarer neoplasms globally, yet it is relatively frequent in some regions,
including parts of South-Eastern Asia and a number of provinces in
South-Eastern China [1]. Radiotherapy (RT) is the primary modality
for the treatment of NPC. High local control and overall survival
could be achieved by RT alone or RT in combination with
chemotherapy. As survival time increased with improvement in
management of this disease, the quality of post-RT life has become a
matter of growing concern.
Sensorineural hearing loss (SNHL) has been recognized as an important
adverse effect of treatment for patient with NPC [2–6]. SNHL can occur
immediately or in months to years after RT, and plateaus after 18 to 24
months [7,8]. Radiation damage to hearing apparatus is believed to result
in SNHL. In recent years, intensity-modulated radiotherapy (IMRT),
which can lead to reduced dose to the hearing apparatus [9,10], has
become a standard RT technique for NPC.
Cisplatin is a cytotoxic agent and radiation sensitizer for the
treatment of NPC. The addition of cisplatin-based chemotherapy to
RT is recommended for stage III and IVa, or even stage II [11].
However, one of the major side effects of cisplatin is SNHL. Cisplatin
and RT might act in synergy and result in an increased risk of SNHL
[12–16]. The relative contribution to SNHL of IMRT or cisplatin
chemotherapy remains undefined. It has been reported that radiation
dose [2,17], cisplatin dose used at each cycle [18], or both radiation dose
and the concurrent cisplatin dose [19] were useful factors to determine
SNHL. However, these reports were based on clinical data with either
small patient numbers or short follow-up period, and were not
specifically fromNPC treatments. It is known that RT for NPC is quite
different from that for other head and neck cancers, as the radiation dose
to the auditory apparatus is often higher for NPC treatment. Clearly,
more mature data from longer follow-up for NPC treatment are needed
to identify the relative contribution to SNHL from each parameter. The
main purpose of this study was to evaluate the incidence of SNHL with
a median follow-up time of 5 years after combined IMRT and
cisplatin-based chemotherapy, and to assess various patient-related,
treatment-related, and dosimetric parameters associated with SNHL.
Material and Methods
Patient Selection
The Institutional Review Board of Sun Yat-sen University Cancer
Center approved the study and consent procedure before starting.
Written informed consent was given by each participant for their clinical
records to be used in this study. We reviewed the medical records of 51
patients with NPC who were treated between 2004 and 2009. Patients
were selected based on the following inclusion criteria: 1) over 18 years
old, 2) histologically diagnosed as havingNPC stage IIa to IVb according
to the American Joint of Cancer Committee (2002), and 3) patients had
taken hearing test before treatment. Exclusion criteria included the
following: 1) history of hypertension or diabetes, 2) recurrence or
metastasis during follow-up, and 3) patients who had middle ear disease
or severe hearing impairment before treatment. Whether the patient has
secretary otitis media (SOM) was also recorded at the time of follow-up.Figure 1. Delineation of (1) internal auditory canal, (2) inner ear, and
(3) cochlea.Radiation Therapy
All selected patients received curative IMRT as described by Xiao
et al. [20]. Briefly, patients were positioned supine and immobilizedfrom head to neck with a thermoplastic mask in both computed
tomography simulation and treatment delivery. The planning
computed tomography was acquired with a slice thickness of 3 mm
and was transferred to a treatment-planning system (CORVUS 3.0/
3.2, NOMOS Corp., Cranberry Township, PA) for IMRT planning.
The gross tumor volume (GTV) was defined according to diagnostic
magnetic resonance imaging, computed tomography and physical
examination. The clinical target volume 1 (CTV1) was defined as the
nasopharynx GTV plus a 5- to 10-mm margin, whereas CTV2 was
the CTV1 plus a 5- to 10-mm margin except 2 to 3 mm posteriorly,
including the elective neck area. Planning target volumes for all gross
tumor volumes and CTVs were generated automatically after
delineation of tumor targets according to the immobilization and
localization uncertainties. Organs at risk (OARs) were delineated
from the planning computed tomography. In particular, the inner ear,
cochlea, and internal auditory canal (IAC) were delineated using bone
window (window width = 2000 HU, window level = 400 HU).
Figure 1 shows an example of these contours. IMRT plans were
generated with a prescribed dose of 68 Gy in 30 fractions to the
GTV, 60 to 64 Gy to CTV1 and 50 to 54 Gy to CTV2. The doses to
OARs were minimized without sacrificing target coverage.
For this analysis, the dosimetric treatment plans were transferred to
the Computational Environment for Radiological Research (CERR
4.0 beta 4) [21] using RTOG file format. To identify factors of being
appropriate dosimetric correlation with SNHL, a series of radiation
dosimetric parameters, including mean dose, minimum dose,
maximum dose, median dose, percentage volume receiving at least
x Gy (Vx), and minimum dose to x cubic centimeter of highest
dose volume (Dxml) were calculated for the inner ear, cochlea, and
IAC from the dosimetric plan for each patient. In addition, the
concept of the equivalent uniform dose (EUD) was introduced to
consider the overall effect of a nonuniform dose distribution for a
given end point [22]. The EUD can be calculated based on dose




i Þ1=a , where vi is the
fractional organ volume receiving a dose Di and a is a tissue-specific
parameter that describes the volume effect [23–26]. This calculation
reduces dose volume histogram into a single parameter, EUD. EUD
was calculated with a series of “a” values for inner ear, cochlea, and
IAC for correlation study with SNHL.
Table 1. Correlation of Patient- and Treatment-Related Factors and SNHL (102 Ears)
Variables SNHL in Ears SNHL in Patients
SNHL/No OR 95% CI P SNHL/No OR 95% CI P
Age (years)
N40 11/45 5.38 1.28-25.67 .034 7/21 7.33 0.83-64.80 .059
≤40 2/44 1 1/22 1
Gender
Male 9/67 0.74 0.21-2.64 .735 5/33 0.51 0.10-2.49 .327
Female 4/22 1 3/10 1
T stage (UICC 2002)
1-3 6/72 0.20 0.06-0.68 .011 4/35 0.23 0.05-1.12 .076
4 7/17 1 4/8 1
Stage (UICC 2002)
IIa-III 8/68 0.31 0.15-1.67 .308 5/33 0.51 0.10-2.49 .404
IVa-IVb 5/21 1 3/10 1
Treatment
CCRT 2/42 .015 1/21 .095
IC → CCRT 9/45 6/21
IC → CCRT → AC 2/2 1/1
Cumulative cisplatin dose (mg/m2)
More than 200 11/35 8.49 1.77-40.61 .003 7/16 5.67 1.05-30.84 .061
Less than 200 2/54 1 2/26 1
Cisplatin prescribed regimen in CCRT
Weekly cisplatin 0/16 .213 1/6 0.88 0.09-8.49 1.000
Every 3 wk 13/73 7/37 1
Carboplatin
With carboplatin 3/19 1.11 0.28-4.42 1.000 2/9 1.26 0.22 -7.33 .557
Without carboplatin 10/70 1 6/34 1
Treatment time
Within 6 wk 7/27 2.68 0.82-8.72 .118 4/13 2.31 0.50-10.67 .416
More than 6 wk 6/62 1 4/30 1
Abbreviations: CT, chemotherapy; CCRT, concurrent chemoradiotherapy; IC → CCRT, induction chemotherapy followed by chemoradiotherapy; IC → CCRT → AC, induction chemotherapy
followed by chemoradiotherapy plus adjuvant chemotherapy; UICC, Union for International Cancer Control.
Fisher’s exact test was used for comparison.
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Fifty-one patients received combined cisplatin-based chemother-
apy, including neoadjuvant, concurrent, and adjuvant use of cisplatin.
Cisplatin was given at a dose of 80 mg/m2 every 3 weeks or 40 mg/
m2/wk during the course of RT. The mean value of cumulative
cisplatin doses was 215.50 ± 107.16 mg/m2 (ranged from 80 to
630 mg/m2, median: 160 mg/m2). Twenty-seven received induction
chemotherapy followed by the concurrent chemoradiotherapy. The
induction chemotherapy consists of two or three cycles of paclitaxel
135 mg/m2 and carboplatin (area under the curve = 6) every 3 three
weeks, or cisplatin 80 mg/m2 on day 1 and 5-fluorouracil 3.5 g/m2
by continuous intravenous infusion on days 2 to 4 every 3 weeks.
Two patients received the induction chemotherapy, followed by
chemoradiotherapy plus adjuvant chemotherapy. Adjuvant chemo-
therapy plan included cisplatin 80 mg/m2 on day 1 and 5-fluoro-
uracil 3.5 g/m2 by continuous intravenous infusion on days 2 to 4
every 3 weeks for three to four cycles.
Hearing Assessment
Pure tone air and bone conduction (BC) audiometry, otoscopy,
and tympanometry were performed. The air conduction threshold
was measured at 0.25 to 8 kHz, and BC threshold was measured at
0.5 to 4 kHz. BC threshold at 4 kHz was selected to represent the
high-frequency loss. The pure tone average (PTA), an average of
threshold levels at 0.5, 1, and 2 kHz, was chosen to reflect the
low-frequency loss. Middle ear function was evaluated by clinical
examination, pure tone auditomery (air-bone gap N 10 dB), and
tympanometry. Significant SNHL was defined if the increase in
hearing threshold was ≥15 dB at low frequencies (PTA).Incidence of SNHL was recorded on per ear basis. To assess the
relationship between radiation dose and SNHL, each ear was analyzed
independently.
Statistical Analysis
The follow-up time, starting from the completion day of IMRT,
ranged from28 to 84 months (median: 60 months). The chi-square test
or Fisher’s exact test (when expected count b 5) was used for
comparison of categorical data. To calculate EUD, the value of 1/a
was selected from 0.001 to 1. Univariate logistic regression was used to
determine the best 1/a value for the EUD calculation. Pearson
correlation was used to analyze its correlation with other parameters.
Receiver operating characteristic curves were used to calculate sensitivity
and specificity at each cutoff value of the dosimetric parameters. The
optimal cutoff value is achieved when the sum of the sensitivity and
specificity reaches a maximum value. Repeated-measures logistic
regression was used to handle the nonindependent data sets. The binary
logistic regression analysis was performed to determine the clinical
factors and dosimetric parameters for SHNL prediction. P b .10 was
used as the cutoff value of statistical significance for variable selection in
the univariable modeling. SNHL ear was considered as outcome
variable. P value of less than .05 was considered statistically significant.
The data processing and statistical analyses were performed using SPSS
software (Version 15.0, SPSS Inc., Chicago, IL).
Results
Audiological Assessment and the Incidences of Postradiation SNHL
Fifty-one patients were reviewed in this study, with a median age of
42 years old ranging from 25 to 70, including 1 (2%) stage IIa, 3





P OR 95% CI
V30 69.0% 15.7% (13/83) 0.0% (0/19) .120 * - -
V40 32.0% 15.1% (8/53) 10.2% (5/49) .559 1.56 0.48-5.15
V50 14.0% 23.1% (7/37) 9.0% (6/65) .217 3.05 0.71-7.45
V60 35.0% 21.1% (3/18) 12.6% (10/84) .696 * 1.48 0.36-6.03
V70 1.0% 15.4% (2/13) 12.4% (11/89) .670 * 1.29 0.25-6.60
Mean dose 38Gy 17.3% (9/52) 8.0% (4/50) .236 2.41 0.69-8.39
Dmin 32.2Gy 15.4% (6/39) 11.1% (7/63) .553 2.11 0.45-4.70
Dmax 54.0Gy 18.4% (7/38) 9.4% (6/64) .225 2.18 0.68-7.06
Median dose 34.0Gy 17.9% (13/82) 0.0% (0/20) .067 * - -
EUD (a=100) 52.0Gy 21.6% (7/37) 7.7% (6/65) .063 * 3.30 1.00-11.00
D0.100 ml 39.8Gy 20.0% (11/55) 4.3% (2/47) .017 5.63 1.18-26.85
D0.035 ml 50.0Gy 23.1% (8/38) 9.0% (5/64) .053 3.15 0.95-10.45
Abbreviations: Dmin: minimum dose; Dmax: maximum dose.
* Fisher’s exact test was used.
Translational Oncology Vol. 8, No. 6, 2015 Hearing Loss after NPC treatment Wang et al. 459(5.9%) stage IIb, 34 (66.7%) stage III, 10 (19.6%) stage IVa, and 3
(5.9%) stage IVb NPCs. Histopathological analysis showed 4 WHO
type I, and 47 types II and III.
Thirteen ears (13/102, 12.7%) in eight patients experienced
low-frequency SNHL, and 43 ears (43/102, 42.2%) in 31 patients had
high-frequency SNHL. The subjective hearing loss was present in 38
(37.3%) ears in 22 patients, and tinnitus was found in 15 (14.7%) ears
in 9 patients. Forty-five (44.1%) ears in 34 patients had SOM.
Air-bone gaps of N 10 dB were present in 37 (36.2%) ears.
The time interval used for assessing hearing varied from 28 to
84 months after radiotherapy. The median interval between hearing test
and the end of the radiochemotherapy was 51 months (range: 28-69
months, 50.2 ± 11.9) and 61 months (range: 28-84 months, 58.7 ±
12.8) for patients with and without SNHL, respectively (P = .027).
There were 16.7% (1/6), 22.2% (4/18), 20% (6/30), 0% (0/36),
and 16.7% (2/12) ears being diagnosed with SNHL at the time
interval of 28 to 36 months, 37 to 48 months, 49 to 60 months, 61 to
72 months, and 73 to 84 months, respectively. There were 54 ears
whose hearing was assessed at 28 to 60 months after radiotherapy, 11
of which was found to have SNHL (20.4%). There were 48 ears
whose hearing was assessed at 61 to 84 months after radiotherapy,
and SNHL was present in 2 ears (4.2%) (odds ratio [OR]: 5.88, 95%
confidence interval [CI]: 1.23-28.08, P = .017).
The median treatment durations (for the entire concurrent
radiation and chemotherapy) were 43 days (range: 40-50 days,
44.2 ± 3.3) and 44 days (range: 39-57 days, 45.6 ± 4.3) for patients
with and without SNHL, respectively (P = .239).
Correlation of Patient- and Treatment-Related Factors and
SNHL
Table 1 shows the correlation factors with the incidence of SNHL.
The SNHL incidence was significantly greater in patients with
age N 40, T-stage 4, and a cumulative cisplatin dose N 200 mg/m2.
Correlation of SOM and SNHL
To assess the relationship between SOM and SNHL, each ear was
analyzed independently. It was found that SNHL was present in 11 of
the 45 (24.4%) ears with SOM, and in 2 of the 57 (3.5%) ears
without SOM (OR: 8.90, 95% CI: 1.86-42.60, P = .002).Table 2. Summary of Dosimetric Parameters (102 Ears)
Parameter Inner Ear Coch
SNHL Non-SNHL SNH
Volume (ml) 3.11 ± 1.05 2.78 ± 0.87 0.33
Mean dose (Gy) 39.42 ± 10.12 37.90 ± 11.39 44.51
Minimum dose (Gy) 22.39 ± 7.86 21.47 ± 7.21 35.55
Maximum dose (Gy) 60.38 ±8.19 58.56 ±10.68 54.93
Median dose (Gy) 40.98 ± 8.46 38.23 ± 9.53 44.93
EUD (Gy) 49.13 ± 12.22 47.22 ±10.69 52.58
D0.1 ml (Gy) 53.92 ± 11.25 53.22 ±11.25 48.72
D0.035 ml (Gy) 56.46 ± 10.91 55.78 ±11.43 52.52
V30 (%) 68.99 ± 20.43 61.66 ±25.16 91.40
V40 (%) 43.64 ± 30.26 34.87 ±30.33 52.99
V50 (%) 22.44 ± 29.89 17.92 ±27.99 29.67
V60 (%) 9.18 ± 18.85 9.16 ±19.57 17.35
V70 (%) 1.34 ± 3.34 3.24 ±8.78 1.53
†Two-sided P b .05.
EUD was calculated using a = 100 for cochlea and a = 16.7 for inner ear.Correlation of Radiation Dosimetric Parameters and SNHL
To assess the relationship between radiation dose and SNHL, each
ear was analyzed independently. A series of radiation dosimetric
parameters for three OARs—cochlea, inner ear, and IAC—that were
thought to relate to SNHL is tabulated in Table 2. The correlation
analysis suggested that D0.1 ml of cochlea was associated with SNHL
(Table 3). Univariate logistic regression show that the EUD of
cochlea was mostly significant for determining SNHL when the EUD
was calculated with parameter a = 100 (P = .063). The calculated
EUD values were found to correlate with the maximum dose,
D0.035 ml, median dose, mean dose, and D0.1 ml (r2 = 0.999,
0.984, 0.972, 0.971, and 0.960, respectively, with all Ps b .001).
The incident probability of SNHL was plotted against the correlated
radiation dosimetric parameters for cochlea in Figure 2.
The same correlation analysis was performed for the inner ear. It
was found that the parameters D0.1 ml, D0.035 ml, EUD, V50,
maximum dose, V40, and median dose of the inner ear were
associated with SNHL (Table 4). The probability of SNHL was
plotted against these parameters of inner ears in Figure 3.lea IAC
L Non-SNHL SNHL Non-SNHL
± 0.08† 0.27 ± 0.07 0.29 ± 0.09 0.26 ± 0.07
± 13.52 42.81 ± 12.76 41.66 ± 11.58 41.43 ± 13.11
± 13.17 34.65 ± 12.86 33.13 ± 12.40 33.89 ± 13.10
± 10.65 52.08 ± 11.83 51.38± 10.68 49.55 ± 12.57
± 11.48 43.06 ± 12.37 41.63± 11.56 41.41 ± 12.99
± 10.40 49.90 ± 11.63 - -
± 13.53 44.37 ± 13.03 43.72 ± 13.16 41.29 ± 15.29
± 12.62 48.13 ± 12.51 47.44 ± 12.92 45.42 ± 11.19
± 11.26 84.63 ± 24.17 86.26 ± 17.23 81.74 ± 26.62
± 36.90 46.71 ± 38.63 42.10± 41.16 40.11 ± 39.50
± 41.38 23.92 ± 38.62 25.95± 41.75 21.30 ± 38.41
± 34.73 16.29 ± 35.25 11.54 ± 28.31 14.85 ± 34.58
± 5.18 4.80 ± 16.59 0.57 ± 2.07 5.11 ± 16.95
Figure 2. The incidence of SNHL versus radiation dosimetric
parameters of cochlea. Significant hearing loss was defined as
≥15-dB increase in BC threshold at 0.5 to 2 kHz (PTA).
Figure 3. The incidence of sensorineural hearing versus radiation
dosimetric parameters of inner ear. Significant hearing loss was
defined as ≥15-dB increase in BC threshold at 0.5 to 2 kHz (PTA).
460 Hearing Loss after NPC treatment Wang et al. Translational Oncology Vol. 8, No. 6, 2015The correlation analysis performed for IAC indicated that none of
the radiation dosimetric parameters of IAC had correlated signifi-
cantly with SNHL (P = .065-.852).
Multivariate Analysis for Factors Associated with SNHL
Multivariate analysis showed that accumulative cisplatin dose
(≥200 mg/m2), radiation D0.1 ml of cochlea (≥39.8Gy), and SOM
(P = .035, .022 and .012, respectively) were determining factors for
SNHL (Table 5, Cox and Snell R2 = 0.330, Nagelkerke R2 = 0.619.)
Discussion
The incidences of SNHL after IMRT for NPC were reported to be
37% to 51.2% at high frequencies and 6% to 22% at low frequencies
[9,17,19,27]. They might increase with more widespread use of
combined IMRT and cisplatin chemotherapy. In our study, all
patients received combined IMRT and cisplatin-based chemotherapy,
and the incidence is concordant with other literature [14,28,29].
Attention was paid to the low-frequency SNHL in this study, as the
patients with low-frequency SNHL may experience subjective
hearing loss in their social life, reducing the quality of life.
Cisplatin is known to cause SNHL. It has been reported that





P OR 95% CI
V30 62.2% 17.0% (8/47) 9.1% (5/55) .231 2.44 0.62-6.77
V40 22.0% 18.3% (11/60) 4.8% (2/42) .043 4.49 0.94-21.44
V50 2.4% 19.0% (11/58) 4.5% (2/44) .031 4.92 1.03-23.46
V60 0.16% 15.6% (5/32) 11.4% (8/70) .555 1.44 0.43-4.79
V70 6.1% 10.5% (2/19) 13.3% (11/83) 1.000 * 0.77 0.16-3.80
Mean dose 35.0Gy 17.0% (8/47) 9.1% (5/55) .231 2.05 0.62-6.77
Dmin 18.8Gy 16.4% (9/55) 8.5% (4/47) .236 2.10 0.60-7.33
Dmax 56.8Gy 19.6% (10/51) 5.9% (3/51) .038 3.90 1.01-15.14
Median dose 36.8Gy 20.4% (11/54) 4.2% (2/48) .014 5.88 1.23-28.08
EUD (a=16.7) 43.5Gy 21.1% (12/57) 2.2% (1/45) .005 11.7 1.46-96.01
D0.1 ml 48.0Gy 19.4% (12/62) 2.5% (1/40) .013 9.36 1.17-75.11
D0.035 ml 51.4Gy 19.6% (11/56) 4.3% (2/46) .021 5.38 1.13-25.67
* Fisher’s exact test was used.200 mg/m2 [30,31], and a 'plateau' phenomenon is observed when
the cisplatin dose reaches 600 mg/m2 [32]. However, the effect of
cumulative cisplatin dose on SNHL after combined modality therapy
was not seen in some studies [3,4,33,34] where few patients received
cisplatin during RT or a low dose was administrated. Low-dose
cisplatin to RT might not increase the risk of SNHL. In our study,
relatively high doses of cisplatin were administrated to most of the
patients. Increased SNHL was observed in patients receiving
cumulative cisplatin dose N 200 mg/m2 for the neoadjuvant,
concurrent, and adjuvant use of cisplatin. Unlike the data reported
for cisplatin, the plateau was not observed in this study.
Carboplatin has been described as an agent with potential to cause
SNHL [35]. However, in our study, the patients who received
carboplatin chemotherapy before radiotherapy had no increased risk of
SNHL. Eleven patients received the carboplatin chemotherapy before
radiotherapy. SNHL was present in 2 of them (18.2%) and in 6 of the
40 (15%) patients without carboplatin chemotherapy (P = .557).
Sumitsawan and his colleagues also reported that radiation combined
with carboplatin did not increase SNHL compared with radiation alone
[28], which might support that the carboplatin has less ototoxicity.
Threshold radiation doses for SNHL vary among studies [36]. Most
studies only investigated the correlation of mean dose of cochlea,
whereas few explored other radiation dosimetric parameters. In this
study, we examined a series of radiation dosimetric parameters for three
relevant OARs and found that the parameters describing a high dose
portion of the distribution, such as V50, D0.1 ml, D0.035 ml, or
maximum dose of cochlea and inner ear, were associated with SNHL.
Furthermore, the EUD calculation for cochlea indicated that EUDTable 5. Logistic Regression of Radiation Dosimetric Parameters and Clinical Factor on SNHL
(102 Ears)
Parameters B SE Wald P Exp(B) 95% CI
Accumulative cisplatin dose
≥200 mg/m2
3.148 1.491 4.458 .035 23.290 1.253-432.775
SOM 3.231 1.291 6.262 .012 25.293 2.014-317.611
D0.1 ml of cochlea≥39.8 0.846 0.369 5.27 .022 2.33 1.13-4.80
Abbreviation: IE, inner ear.
Translational Oncology Vol. 8, No. 6, 2015 Hearing Loss after NPC treatment Wang et al. 461extremely closed to the maximum dose and D0.035 ml, with the best
fitting parameter a = 100. This indicated that cochlea might be a
serially organized organ; themean dose for cochleamight not be the best
predicting factor for radiation-induced SNHL. As the cochlea is
proximal to the NPC target, it usually locates in the high-dose region.
This may result in that the dose parameters describing the high-dose
portion of the dose distribution for inner ear have a similar correlation
with the SNHL as those for the cochlea. None of the radiation dose
parameters of IAC was found to significantly correlate to SNHL. This
may be because IAC is usually in the low-dose region as it is proximal to
the brain stem.
One concern for a small structure such as cochlea is that the radiation
dose actually received by cochlea can be sensitive to the daily positioning
variation. To address the concern, an effort was made to assess the effect
of daily setup variation on the cochlea dose. Considering a daily setup
variation of 3 mm, the resulting variation in the daily dose delivered to
the cochlea is substantial only when the cochlea is in the region with a
sharp dose gradient. For a big portion of the cases studied, the dose
gradient across the cochlea was either flat or small, resulting in a small
daily variation due to the setup uncertainty. Furthermore, as the daily
setup uncertainty is random in nature [37], the effect of the daily dose
variation on the accumulative dose would be reduced.
Apart from RT and cisplatin, patient-related factors such as age
[3,4,33,38,39] and SOM [3,7,36] have been reported to affect
SNHL. The current study also revealed that patients with age N 40 or
SOM experienced greater SNHL.
The time interval used for assessing hearing is very wide. It is
possible that time might have a role in the severity of SNHL. It is
reported that SNHL might be irreversible, and persistent hearing loss
would continue to increase with time [36]. However, ears with
SNHL had even shorter exposure history than those without SNHL
in our study. Perhaps only one (not sequential) hearing test was
performed during the long-term follow-up, and pure tone audiometry
was performed when the patient came back to follow-up. Selective
bias may exist, as the patient who suspected a problem might be more
willing to undergo audiometry test. That would partly explain why
ears with SNHL had even shorter exposure history.
Another limitation of the current study is that the ear rather than the
patient was adopted as the observation unit in our study. Considering
that the ears of one patient are not independent and subject to the same
therapy procedure, there was intracluster correlation among observa-
tions, which would lower statistical power. Furthermore, it is unknown
whether there is any confounding effect of SOM. Lastly, for patients
with advanced diseases, they may not survive long enough for the
observation of SNHL as it is a late effect.
In conclusion, for NPC patients treated with IMRT and
cisplatin-based chemotherapy, there might be a significant increase
in the incidence of SNHL among patients who received cumulative
cisplatin dose N 200 mg/m2, who suffered from SOM, and in whom
the minimum radiation dose to 0.1 ml highest dose volume
(D0.1 ml) of cochlea was ≥ 39.8 Gy. In addition, various radiation
dosimetric parameters for cochlea and those describing high-dose
portions of the dose distribution, such as D0.035 ml and D0.1 ml,
might correlate with SNHL. The EUD for cochlea might be
dominated by the maximum dose, implying that cochlea might be a
serially organized organ. The study provides new information on
treatment-related SNHL, particularly the new relationships between
radiation parameters and SNHL. The information will be useful for
future prospective studies.References
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